CHM CDH17 Phase 1 clinical trial update - New DL 3 data
Open PDF
| Stock | Chimeric Therapeutics Ltd (CHM.ASX) |
|---|---|
| Release Time | 16 Jul 2026, 9:04 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
CHM CDH17 Phase 1 clinical trial update
Key Points
- Four patients treated at Dose Level 3 of 450 million CAR-T cells
- Promising interim data from two patients showing tumor shrinkage
- One patient maintained Stable Disease for six months
- No new safety signals reported
Full Summary
Chimeric Therapeutics has provided an update on its ongoing Phase 1/2 clinical trial for CHM CDH17, a CAR-T cell therapy targeting CDH17 in gastrointestinal and neuroendocrine tumors. Four patients have been treated at the highest dose level, 450 million CAR-T cells. Preliminary results from two patients show tumor shrinkage ranging from 17% to 40% in individual lesions. One patient has maintained stable disease for six months, and another for four months. The safety profile remains favorable with no new safety signals reported. The trial is ongoing, with two more patients to be dosed at this dose level. The company expects to complete dosing for all six patients by the end of 2026.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In